Hannah Valantine - Nov 12, 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
/s/ Will Solis, Attorney-in-Fact
Stock symbol
BBIO
Transactions as of
Nov 12, 2025
Transactions value $
-$449,028
Form type
4
Date filed
11/14/2025, 04:50 PM
Previous filing
Jun 30, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Valantine Hannah Director C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO /s/ Will Solis, Attorney-in-Fact 2025-11-14 0001855608

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Options Exercise $1.23M +25.5K +341.38% $48.45 32.9K Nov 12, 2025 Direct
transaction BBIO Common Stock Sale -$1.68M -25.5K -77.34% $66.07 7.47K Nov 12, 2025 Direct
holding BBIO Common Stock 398 Nov 12, 2025 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (Right to Buy) Options Exercise $0 -25.5K -50% $0.00 25.5K Nov 12, 2025 Common Stock 25.5K $48.45 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vested and became exercisable in three annual installments after October 25, 2021.

Remarks:

Exhibit 24 - Power of Attorney